Definium Therapeutics, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.97 USD
−108.68 M USD
0.00 USD
73.44 M
About Definium Therapeutics, Inc.
Sector
Industry
CEO
Robert Barrow
Website
Headquarters
New York
Founded
2010
Identifiers
3
ISIN CA24477V1058
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DFTX is 15.61 USD — it has increased by 2.40% in the past 24 hours. Watch Definium Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Definium Therapeutics, Inc. stocks are traded under the ticker DFTX.
DFTX stock has risen by 10.01% compared to the previous week, the month change is a 28.17% rise, over the last year Definium Therapeutics, Inc. has showed a 131.95% increase.
We've gathered analysts' opinions on Definium Therapeutics, Inc. future price: according to them, DFTX price has a max estimate of 61.00 USD and a min estimate of 16.00 USD. Watch DFTX chart and read a more detailed Definium Therapeutics, Inc. stock forecast: see what analysts think of Definium Therapeutics, Inc. and suggest that you do with its stocks.
DFTX stock is 4.06% volatile and has beta coefficient of 1.75. Track Definium Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Definium Therapeutics, Inc. there?
Yes, you can track Definium Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Definium Therapeutics, Inc. is going to release the next earnings report on Mar 5, 2026. Keep track of upcoming events with our Earnings Calendar.
DFTX earnings for the last quarter are −0.78 USD per share, whereas the estimation was −0.50 USD resulting in a −55.59% surprise. The estimated earnings for the next quarter are −0.49 USD per share. See more details about Definium Therapeutics, Inc. earnings.
Definium Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
DFTX net income for the last quarter is −67.27 M USD, while the quarter before that showed −42.74 M USD of net income which accounts for −57.37% change. Track more Definium Therapeutics, Inc. financial stats to get the full picture.
No, DFTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2026, the company has 74 employees. See our rating of the largest employees — is Definium Therapeutics, Inc. on this list?
Like other stocks, DFTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Definium Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Definium Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Definium Therapeutics, Inc. stock shows the buy signal. See more of Definium Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.